Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the Quarterly Period Ended September 30, 2022			URITIES EXCHANGE ACT OF 1934
		OR	
	TRANSITION REPORT PURSUANT TO SECT	ON 13 OR 15(d) OF THE SEC	LIRITIES EXCHANGE ACT OF 1934
	For the Transition Period From to	3 10 3 1 10 a 10 a 11 a 11 a 1 a 1 a 1 a 1 a 1	ORTHEO EXCHANGE ACT OF 1864
		mmission File Number 001-37	7845
	1410000		-
	MICROS	OFT CORPO	DRATION
	WASHINGTON (STATE OF INCORPORATION)		91-1144442
	,	OFT WAY, REDMOND, WASHINGTO (425) 882-8080 www.microsoft.com/investor	(I.R.S. ID) ON 98052-6399
Secur	rities registered pursuant to Section 12(b) of the Act:		
	of each class	Trading Symbol	Name of exchange on which registered
Common stock, \$0.00000625 par value per share 3.125% Notes due 2028 2.625% Notes due 2033		MSFT MSFT MSFT	NASDAQ NASDAQ NASDAQ
prece	ate by check mark whether the registrant (1) has filed all I ding 12 months (or for such shorter period that the registrates. Yes $oxed{\boxtimes}$ No $oxdot$	reports required to be filed by Section ant was required to file such reports),	on 13 or 15(d) of the Securities Exchange Act of 1934 during the , and (2) has been subject to such filing requirements for the pas
	ate by check mark whether the registrant has submitted ele 2.405 of this chapter) during the preceding 12 months (or fo		e required to be submitted pursuant to Rule 405 of Regulation S-1 ant was required to submit such files). Yes $\ oxdot$ No $\ \Box$
growtl			on-accelerated filer, a smaller reporting company, or an emerging g company," and "emerging growth company" in Rule 12b-2 of the
	e Accelerated Filer ⊠ accelerated Filer □		Accelerated Filer □ Smaller Reporting Company □ Emerging Growth Company □
	emerging growth company, indicate by check mark if the ricial accounting standards provided pursuant to Section 13(extended transition period for complying with any new or revised
Indica	ate by check mark whether the registrant is a shell compan	y (as defined in Rule 12b-2 of the Exc	change Act). Yes □ No ⊠
Indica	ate the number of shares outstanding of each of the issuer'	s classes of common stock, as of the	e latest practicable date.
Class			Outstanding as of October 20, 2022
	non Stock, \$0.0000625 par value per share		7,454,473,144 shares

NOTE 14 — CONTINGENCIES

U.S. Cell Phone Litigation

Microsoft Mobile Oy, a subsidiary of Microsoft, along with other handset manufacturers and network operators, is a defendant in 46 lawsuits, including 45 lawsuits filed in the Superior Court for the District of Columbia by individual plaintiffs who allege that radio emissions from cellular handsets caused their brain tumors and other adverse health effects. We assumed responsibility for these claims in our agreement to acquire Nokia's Devices and Services business and have been substituted for the Nokia defendants. Nine of these cases were filed in 2002 and are consolidated for certain pre-trial proceedings; the remaining cases are stayed. In a separate 2009 decision, the Court of Appeals for the District of Columbia held that adverse health effect claims arising from the use of cellular handsets that operate within the U.S. Federal Communications Commission radio frequency emission guidelines ("FCC Guidelines") are pre-empted by federal law. The plaintiffs allege that their handsets either operated outside the FCC Guidelines or were manufactured before the FCC Guidelines went into effect. The lawsuits also allege an industry-wide conspiracy to manipulate the science and testing around emission guidelines.

In 2013, the defendants in the consolidated cases moved to exclude the plaintiffs' expert evidence of general causation on the basis of flawed scientific methodologies. In 2014, the trial court granted in part and denied in part the defendants' motion to exclude the plaintiffs' general causation experts. The defendants filed an interlocutory appeal to the District of Columbia Court of Appeals challenging the standard for evaluating expert scientific evidence. In October 2016, the Court of Appeals issued its decision adopting the standard advocated by the defendants and remanding the cases to the trial court for further proceedings under that standard. The plaintiffs have filed supplemental expert evidence, portions of which were stricken by the court. A hearing on general causation took place in September of 2022.

Other Contingencies

We also are subject to a variety of other claims and suits that arise from time to time in the ordinary course of our business. Although management currently believes that resolving claims against us, individually or in aggregate, will not have a material adverse impact in our consolidated financial statements, these matters are subject to inherent uncertainties and management's view of these matters may change in the future.

As of September 30, 2022, we accrued aggregate legal liabilities of \$264 million. While we intend to defend these matters vigorously, adverse outcomes that we estimate could reach approximately \$500 million in aggregate beyond recorded amounts are reasonably possible. Were unfavorable final outcomes to occur, there exists the possibility of a material adverse impact in our consolidated financial statements for the period in which the effects become reasonably estimable.

NOTE 15 — STOCKHOLDERS' EQUITY

Share Repurchases

On September 18, 2019, our Board of Directors approved a share repurchase program authorizing up to \$40.0 billion in share repurchases. This share repurchase program commenced in February 2020 and was completed in November 2021.

On September 14, 2021, our Board of Directors approved a share repurchase program authorizing up to \$60.0 billion in share repurchases. This share repurchase program commenced in November 2021, following completion of the program approved on September 18, 2019, has no expiration date, and may be terminated at any time. As of September 30, 2022, \$36.1 billion remained of this \$60.0 billion share repurchase program.

We repurchased the following shares of common stock under the share repurchase programs:

(In millions)	Shares	Amount	Shares	Amount
Fiscal Year		2023		2022
First Quarter	17	\$ 4,600	<mark>21</mark> \$	6,200

Washington, D.C. 20549

FORM 10-Q

	_		<u>_</u>			
\boxtimes	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934					
	For the Quarterly Period Ended December 31, 2022					
		OR				
	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934					
	For the Transition Period From to	. ,				
	Con	nmission File Number 001-37	7845			
	MICROS	OFT CORPO	PRATION			
	WASHINGTON (STATE OF INCORPORATION)		– 91-1144442 (I.R.S. ID)			
	,	DFT WAY, REDMOND, WASHINGTO (425) 882-8080 www.microsoft.com/investor	, ,			
Secu	rities registered pursuant to Section 12(b) of the Act:					
Title o	of each class	Trading Symbol	Name of exchange on which registered			
Common stock, \$0.00000625 par value per share 3.125% Notes due 2028 2.625% Notes due 2033		MSFT MSFT MSFT	NASDAQ NASDAQ NASDAQ			
prece	ate by check mark whether the registrant (1) has filed all reeding 12 months (or for such shorter period that the registral ays. Yes $oxtimes$ No $oxdot$	eports required to be filed by Sectiont was required to file such reports),	n 13 or 15(d) of the Securities Exchange Act of 1934 during the and (2) has been subject to such filing requirements for the pas			
(§232	2.405 of this chapter) during the preceding 12 months (or for	such shorter period that the registra				
growt	ate by check mark whether the registrant is a large acceler th company. See the definitions of "large accelerated filer," " ange Act.	ated filer, an accelerated filer, a not accelerated filer," "smaller reporting	n-accelerated filer, a smaller reporting company, or an emerging company," and "emerging growth company" in Rule 12b-2 of the			
Large Accelerated Filer ⊠ Non-accelerated Filer □			Accelerated Filer □ Smaller Reporting Company □ Emerging Growth Company □			
	emerging growth company, indicate by check mark if the recial accounting standards provided pursuant to Section 13(a		extended transition period for complying with any new or revised			
Indica	ate by check mark whether the registrant is a shell company	(as defined in Rule 12b-2 of the Exc	change Act). Yes □ No ⊠			
Indica	ate the number of shares outstanding of each of the issuer's	classes of common stock, as of the	latest practicable date.			
Class			Outstanding as of January 19, 2023			
Com	mon Stock, \$0.00000625 par value per share		7,443,803,533 shares			
-						

NOTE 14 — CONTINGENCIES

U.S. Cell Phone Litigation

Microsoft Mobile Oy, a subsidiary of Microsoft, along with other handset manufacturers and network operators, is a defendant in 46 lawsuits, including 45 lawsuits filed in the Superior Court for the District of Columbia by individual plaintiffs who allege that radio emissions from cellular handsets caused their brain tumors and other adverse health effects. We assumed responsibility for these claims in our agreement to acquire Nokia's Devices and Services business and have been substituted for the Nokia defendants. Nine of these cases were filed in 2002 and are consolidated for certain pre-trial proceedings; the remaining cases are stayed. In a separate 2009 decision, the Court of Appeals for the District of Columbia held that adverse health effect claims arising from the use of cellular handsets that operate within the U.S. Federal Communications Commission radio frequency emission guidelines ("FCC Guidelines") are pre-empted by federal law. The plaintiffs allege that their handsets either operated outside the FCC Guidelines or were manufactured before the FCC Guidelines went into effect. The lawsuits also allege an industry-wide conspiracy to manipulate the science and testing around emission guidelines.

In 2013, the defendants in the consolidated cases moved to exclude the plaintiffs' expert evidence of general causation on the basis of flawed scientific methodologies. In 2014, the trial court granted in part and denied in part the defendants' motion to exclude the plaintiffs' general causation experts. The defendants filed an interlocutory appeal to the District of Columbia Court of Appeals challenging the standard for evaluating expert scientific evidence. In October 2016, the Court of Appeals issued its decision adopting the standard advocated by the defendants and remanding the cases to the trial court for further proceedings under that standard. The plaintiffs have filed supplemental expert evidence, portions of which were stricken by the court. A hearing on general causation took place in September of 2022.

Other Contingencies

We also are subject to a variety of other claims and suits that arise from time to time in the ordinary course of our business. Although management currently believes that resolving claims against us, individually or in aggregate, will not have a material adverse impact in our consolidated financial statements, these matters are subject to inherent uncertainties and management's view of these matters may change in the future.

As of December 31, 2022, we accrued aggregate legal liabilities of \$181 million. While we intend to defend these matters vigorously, adverse outcomes that we estimate could reach approximately \$500 million in aggregate beyond recorded amounts are reasonably possible. Were unfavorable final outcomes to occur, there exists the possibility of a material adverse impact in our consolidated financial statements for the period in which the effects become reasonably estimable.

NOTE 15 — STOCKHOLDERS' EQUITY

Share Repurchases

On September 18, 2019, our Board of Directors approved a share repurchase program authorizing up to \$40.0 billion in share repurchases. This share repurchase program commenced in February 2020 and was completed in November 2021.

On September 14, 2021, our Board of Directors approved a share repurchase program authorizing up to \$60.0 billion in share repurchases. This share repurchase program commenced in November 2021, following completion of the program approved on September 18, 2019, has no expiration date, and may be terminated at any time. As of December 31, 2022, \$31.5 billion remained of this \$60.0 billion share repurchase program.

Washington, D.C. 20549

FORM 1	LO-Q
--------	------

☑ QUARTERLY REPORT PURSUANT TO	O SECTION 13 OR 15(d) OF THE SECURITI	ES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 202	3	
	OR	
☐ TRANSITION REPORT PURSUANT TO	O SECTION 13 OR 15(d) OF THE SECURITI	ES EXCHANGE ACT OF 1934
	3 323 13 14 13 3 K 13 (a) 31 THE 3233 KIT	ES EXCHANGE ACT OF 1994
For the Transition Period From to	Commission File Number 001-37845	
MICF	ROSOFT CORPOR	ATION
WASHINGTON (STATE OF INCORPORATION		91-1144442 (I.R.S. ID)
·	: EMICROSOFT WAY, REDMOND, WASHINGTON 980 (425) 882-8080 www.microsoft.com/investor	, ,
Securities registered pursuant to Section 12(b) of the	Act:	
Title of each class	Trading Symbol	Name of exchange on which registered
Common stock, \$0.00000625 par value per share 3.125% Notes due 2028 2.625% Notes due 2033	MSFT MSFT MSFT	NASDAQ NASDAQ NASDAQ
Indicate by check mark whether the registrant (1) has preceding 12 months (or for such shorter period that to 90 days. Yes \boxtimes No \square	s filed all reports required to be filed by Section 13 or he registrant was required to file such reports), and (2	r 15(d) of the Securities Exchange Act of 1934 during the c) has been subject to such filing requirements for the pas
		ed to be submitted pursuant to Rule 405 of Regulation S-Trequired to submit such files). Yes $\ \ \ \ \ \ \ \ \ \ \ \ \ $
		erated filer, a smaller reporting company, or an emerging any," and "emerging growth company" in Rule 12b-2 of the
Large Accelerated Filer ⊠		Accelerated Filer \square
Non-accelerated Filer □		Smaller Reporting Company □ Emerging Growth Company □
If an emerging growth company, indicate by check ma financial accounting standards provided pursuant to S		ed transition period for complying with any new or revised
Indicate by check mark whether the registrant is a she	ll company (as defined in Rule 12b-2 of the Exchange	Act). Yes □ No ⊠
Indicate the number of shares outstanding of each of t	he issuer's classes of common stock, as of the latest p	practicable date.
Class		Outstanding as of April 20, 2023
Common Stock, \$0.00000625 par value per share		7,435,487,575 shares

As of March 31, 2023, we have additional operating and finance leases, primarily for datacenters, that have not yet commenced of \$5.0 billion and \$21.9 billion, respectively. These operating and finance leases will commence between fiscal year 2023 and fiscal year 2030 with lease terms of 1 year to 18 years.

NOTE 14 — CONTINGENCIES

U.S. Cell Phone Litigation

Microsoft Mobile Oy, a subsidiary of Microsoft, along with other handset manufacturers and network operators, is a defendant in 46 lawsuits, including 45 lawsuits filed in the Superior Court for the District of Columbia by individual plaintiffs who allege that radio emissions from cellular handsets caused their brain tumors and other adverse health effects. We assumed responsibility for these claims in our agreement to acquire Nokia's Devices and Services business and have been substituted for the Nokia defendants. Nine of these cases were filed in 2002 and are consolidated for certain pre-trial proceedings; the remaining cases are stayed. In a separate 2009 decision, the Court of Appeals for the District of Columbia held that adverse health effect claims arising from the use of cellular handsets that operate within the U.S. Federal Communications Commission radio frequency emission guidelines ("FCC Guidelines") are pre-empted by federal law. The plaintiffs allege that their handsets either operated outside the FCC Guidelines or were manufactured before the FCC Guidelines went into effect. The lawsuits also allege an industry-wide conspiracy to manipulate the science and testing around emission guidelines.

In 2013, the defendants in the consolidated cases moved to exclude the plaintiffs' expert evidence of general causation on the basis of flawed scientific methodologies. In 2014, the trial court granted in part and denied in part the defendants' motion to exclude the plaintiffs' general causation experts. The defendants filed an interlocutory appeal to the District of Columbia Court of Appeals challenging the standard for evaluating expert scientific evidence. In October 2016, the Court of Appeals issued its decision adopting the standard advocated by the defendants and remanding the cases to the trial court for further proceedings under that standard. The plaintiffs have filed supplemental expert evidence, portions of which were stricken by the court. A hearing on general causation took place in September of 2022.

Other Contingencies

We also are subject to a variety of other claims and suits that arise from time to time in the ordinary course of our business. Although management currently believes that resolving claims against us, individually or in aggregate, will not have a material adverse impact in our consolidated financial statements, these matters are subject to inherent uncertainties and management's view of these matters may change in the future.

As of March 31, 2023, we accrued aggregate legal liabilities of \$177 million. While we intend to defend these matters vigorously, adverse outcomes that we estimate could reach approximately \$600 million in aggregate beyond recorded amounts are reasonably possible. Were unfavorable final outcomes to occur, there exists the possibility of a material adverse impact in our consolidated financial statements for the period in which the effects become reasonably estimable.

NOTE 15 — STOCKHOLDERS' EQUITY

Share Repurchases

On September 18, 2019, our Board of Directors approved a share repurchase program authorizing up to \$40.0 billion in share repurchases. This share repurchase program commenced in February 2020 and was completed in November 2021.

On September 14, 2021, our Board of Directors approved a share repurchase program authorizing up to \$60.0 billion in share repurchases. This share repurchase program commenced in November 2021, following completion of the program approved on September 18, 2019, has no expiration date, and may be terminated at any time. As of March 31, 2023, \$26.9 billion remained of this \$60.0 billion share repurchase program.

Washington, D.C. 20549

FORM 10-Q

\boxtimes	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934				
	For the Quarterly Period Ended September 30, 2023				
		OR			
	TRANSITION REPORT PURSUANT TO SECTIO	N 13 OR 15(d) OF THE SECU	IRITIES EXCHANGE ACT OF 1934		
	For the Transition Period From to				
	Com	mission File Number 001-37	845		
	MICROS	OFT CORPO	RATION		
	WASHINGTON		 91-1144442		
	(STATE OF INCORPORATION)		(I.R.S. ID)		
	ONE MICROSO	FT WAY, REDMOND, WASHINGTO (425) 882-8080 www.microsoft.com/investor	ON 98052-6399		
Secur	rities registered pursuant to Section 12(b) of the Act:				
Title c	of each class	Trading Symbol	Name of exchange on which registered		
Common stock, \$0.00000625 par value per share 3.125% Notes due 2028 2.625% Notes due 2033		MSFT MSFT MSFT	NASDAQ NASDAQ NASDAO		
Indica prece	te by check mark whether the registrant (1) has filed all reg	ports required to be filed by Section	n 13 or 15(d) of the Securities Exchange Act of 1934 during the and (2) has been subject to such filing requirements for the pas		
Indica	,		required to be submitted pursuant to Rule 405 of Regulation S-1 It was required to submit such files). Yes $\ \ \ \ \ \ \ \ \ \ \ \ \ $		
growtl	ate by check mark whether the registrant is a large accelerate th company. See the definitions of "large accelerated filer," "a ange Act.	ated filer, an accelerated filer, a nor accelerated filer," "smaller reporting	n-accelerated filer, a smaller reporting company, or an emerging company," and "emerging growth company" in Rule 12b-2 of the		
Large Accelerated Filer ⊠			Accelerated Filer □		
Non-a	accelerated Filer □		Smaller Reporting Company \square Emerging Growth Company \square		
	emerging growth company, indicate by check mark if the recial accounting standards provided pursuant to Section 13(a)		extended transition period for complying with any new or revised		
Indica	te by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Excl	nange Act). Yes □ No ⊠		
Indica	te the number of shares outstanding of each of the issuer's o	classes of common stock, as of the I	atest practicable date.		
Class			Outstanding as of October 19, 2023		
Comn	non Stock, \$0.0000625 par value per share		7,432,262,329 shares		

NOTE 13 — CONTINGENCIES

U.S. Cell Phone Litigation

Microsoft Mobile Oy, a subsidiary of Microsoft, along with other handset manufacturers and network operators, is a defendant in 46 lawsuits, including 45 lawsuits filed in the Superior Court for the District of Columbia by individual plaintiffs who allege that radio emissions from cellular handsets caused their brain tumors and other adverse health effects. We assumed responsibility for these claims in our agreement to acquire Nokia's Devices and Services business and have been substituted for the Nokia defendants. Nine of these cases were filed in 2002 and are consolidated for certain pre-trial proceedings; the remaining cases are stayed. In a separate 2009 decision, the Court of Appeals for the District of Columbia held that adverse health effect claims arising from the use of cellular handsets that operate within the U.S. Federal Communications Commission radio frequency emission guidelines ("FCC Guidelines") are pre-empted by federal law. The plaintiffs allege that their handsets either operated outside the FCC Guidelines or were manufactured before the FCC Guidelines went into effect. The lawsuits also allege an industry-wide conspiracy to manipulate the science and testing around emission guidelines.

In 2013, the defendants in the consolidated cases moved to exclude the plaintiffs' expert evidence of general causation on the basis of flawed scientific methodologies. In 2014, the trial court granted in part and denied in part the defendants' motion to exclude the plaintiffs' general causation experts. The defendants filed an interlocutory appeal to the District of Columbia Court of Appeals challenging the standard for evaluating expert scientific evidence. In October 2016, the Court of Appeals issued its decision adopting the standard advocated by the defendants and remanding the cases to the trial court for further proceedings under that standard. The plaintiffs have filed supplemental expert evidence, portions of which were stricken by the court. A hearing on general causation took place in September of 2022. In April of 2023, the court granted defendants' motion to strike the testimony of plaintiffs' experts that cell phones cause brain cancer and entered an order excluding all of plaintiffs' experts from testifying. The plaintiffs appealed the court's order in August of 2023.

Irish Data Protection Commission Matter

In 2018, the Irish Data Protection Commission ("IDPC") began investigating a complaint against LinkedIn as to whether LinkedIn's targeted advertising practices violated the recently implemented European Union General Data Protection Regulation ("GDPR"). Microsoft cooperated throughout the period of inquiry. In April 2023, the IDPC provided LinkedIn with a non-public preliminary draft decision alleging GDPR violations and proposing a fine. Microsoft intends to challenge the preliminary draft decision. There is no set timeline for the IDPC to issue a final decision.

Other Contingencies

We also are subject to a variety of other claims and suits that arise from time to time in the ordinary course of our business. Although management currently believes that resolving claims against us, individually or in aggregate, will not have a material adverse impact in our consolidated financial statements, these matters are subject to inherent uncertainties and management's view of these matters may change in the future.

As of September 30, 2023, we accrued aggregate legal liabilities of \$597 million. While we intend to defend these matters vigorously, adverse outcomes that we estimate could reach approximately \$600 million in aggregate beyond recorded amounts are reasonably possible. Were unfavorable final outcomes to occur, there exists the possibility of a material adverse impact in our consolidated financial statements for the period in which the effects become reasonably estimable.

NOTE 14 — STOCKHOLDERS' EQUITY

Share Repurchases

On September 14, 2021, our Board of Directors approved a share repurchase program authorizing up to \$60.0 billion in share repurchases. This share repurchase program commenced in November 2021, has no expiration date, and may be terminated at any time. As of September 30, 2023, \$18.7 billion remained of this \$60.0 billion share repurchase program.